Rhodes Pharmaceuticals, L.P.

1 marketed · 2 in Phase 3

Quick facts

Marketed products

Aptensio XR · Psychiatry/Neurology
Aptensio XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.

Phase 3 pipeline

Drug: PRC-063 · Psychiatry / Neurology
PRC-063 is an extended-release formulation of methylphenidate designed to provide sustained dopamine and norepinephrine reuptake inhibition for ADHD symptom management.
PRC-063 · Psychiatry / Neurology
PRC-063 is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition for ADHD symptom management.

Phase 1 pipeline

PG101

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: